PASADENA, Calif. --(BUSINESS WIRE)--Oct. 31, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented preclinical data at the 2019 North American Cystic Fibrosis Conference (NACFC) on ARO-ENaC, an inhaled RNAi therapeutic being developed as a potential treatment for cystic fibrosis
PASADENA, Calif. --(BUSINESS WIRE)--Oct. 18, 2019-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is hosting a Research & Development (R&D) Day today in New York to discuss its emerging pipeline of RNAi therapeutics that leverage its proprietary Targeted RNAi Molecule Platform (TRiM™) platform.
PASADENA, Calif. --(BUSINESS WIRE)--Oct. 2, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a Research & Development (R&D) Day to discuss its emerging pipeline of RNAi therapeutics that leverage its proprietary Targeted RNAi Molecule (TRIM TM ) platform from
PASADENA, Calif. --(BUSINESS WIRE)--Sep. 30, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: 2019 Cantor Global Healthcare Conference – New York , October 2-4, 2019 October 4 , 10:05 a.m.
PASADENA, Calif. --(BUSINESS WIRE)--Sep. 20, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on September 13, 2019 , the Compensation Committee of the Board of Directors approved "inducement" grants to 17 new
PASADENA, Calif. --(BUSINESS WIRE)--Sep. 16, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented initial top-line clinical data at The Global Summit on Cardiology and Heart Diseases, being held in Dubai , UAE . The data demonstrate that, in two Phase I single-dose clinical studies
PASADENA, Calif. --(BUSINESS WIRE)--Aug. 30, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Baird's 2019 Global Healthcare Conference – New York , September 4-5, 2019 September 4 , 9:40 a.m.
- Arrowhead earns $25 million milestone payment in connection with trial initiation PASADENA, Calif. --(BUSINESS WIRE)--Aug. 28, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that Janssen Pharmaceuticals, Inc. , part of the Janssen Pharmaceutical Companies of Johnson &
PASADENA, Calif. --(BUSINESS WIRE)--Aug. 8, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patient in SEQUOIA (AROAAT2001), a potentially pivotal Phase 2/3 clinical study of ARO-AAT, the company’s second generation subcutaneously administered RNA
- Conference Call and Webcast Today at 4:30 p.m. EDT PASADENA, Calif. --(BUSINESS WIRE)--Aug. 5, 2019-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2019 third quarter ended June 30, 2019 . The company is hosting a conference call at 4:30 p.m.